Hemispherx Biopharma Added to Russell 2000 and 3000

Hemispherx Biopharma (Amex: HEB) announced today that it has been added to the Russell 3000(R) Index effective at the close of business June 30, 1999. The Russell 3000 measures the performance of the 3,000 largest US companies based on total market capitalization, which represents approximately 98% of the investable US equity market. Hemispherx has also been added to the Russell 2000(R) Index, which measures the performance of the 2,000 smallest companies in the Russell 3000 Index. The Russell 2000 represents approximately 11% of the total market capitalization of the Russell 3000 Index. As of the latest reconstitution of the indexes, the average market capitalization was approximately $592 million; the median market capitalization was approximately $500 million. The largest company in the Russell 2000 Index had an approximate market capitalization of $1.4 billion. "Our inclusion in the Russell 2000 and Russell 3000 is a reflection of our dynamic technologic growth," said William A. Carter, M.D., President and CEO of Hemispherx. "It is a testament to the quality of our technology, our employees and the trust of our shareholders that we have reached this milestone." Frank Russell Company, one of the world's leading investment management and advisory firms, provides investment advice, analytic tools and funds to institutional and individual investors in more than 30 countries. Russell's investment management business employs a manager-of-managers approach and has approximately $50 billion in assets under management. Additional information on the Russell indexes can be found on Russell's Web site at http://www.russell.com. About Hemispherx: Hemispherx is a biopharmaceutical company specializing in the new therapeutic approaches to HIV/AIDS, CFS (Chronic Fatigue Syndrome) and hepatitis B/C utilizing the immune system. It has offices in Philadelphia, Belgium and France and new drug development facilities in the Washington D.C. area. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of HEMISPHERX involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. ots Original Text Service: Hemispherx Biopharma, Inc. Internet: http://www.newsaktuell.de Contact: William A. Carter, M.D., CEO & Chairman of Hemispherx Biopharma, Inc., (USA) 215-988-0080; or Media - William Jenks, (USA) 212-232-2222, or fax, (USA) 212-232-3232; or Investor Relations - Sharon Will, (USA) 212-572-0762, or fax, (USA) 212-572-0764 Web site: http://www.hemispherx.com


Prague, Central Bohemia region and Czech Republic


Subscribe for free

Important notice:
Subscribers please note that material bearing the label "PROTEXT" is not part of CTK's news service and is not to be published under the "CTK" label. Protext is a commercial service providing distribution of press releases from clients, who are identified in the text of Protext reports and who bear full responsibility for their contents.